Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 28031519.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis. Surgery for stabilisation was avoided.
Medical subject headings
- Adenocarcinoma
- Antineoplastic Agents
- Bone Neoplasms
- Lung Neoplasms
- Osteogenesis
- Quinazolines
Anatomy
- pelvis